Evidence map›Paper›PMID 31713687›Full record

ArticleMikrochimica acta2019

An electrochemical peptide-based biosensor for the Alzheimer biomarker amyloid-β

Masoud Negahdary, Hossein Heli

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Masoud NegahdaryNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, 7193635899, Iran.
Hossein HeliNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, 7193635899, Iran. hheli7@yahoo.com.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is connected to aggregation of amyloid-β (Aβ) peptide and formation of insoluble plaques in the brain. Aβ level can be monitored as an AD early diagnosis route. In this study, an irregular shaped microporous gold nanostructure with a typical size of 150 × 250 nm was electrodeposited on a polycrystalline gold surface at 0 mV (vs. AgCl) using sodium alendronate. The nanostructure was then characterized by field-emission scanning electron microscopy. An electrochemical peptide-based biosensor was fabricated by immobilizing an Aβ

Indexed as

Alzheimer DiseaseAmino Acid SequenceAmyloid beta-PeptidesBiomarkersBiosensing TechniquesElectrochemical TechniquesGoldHumansLimit of DetectionMetal NanoparticlesPeptide FragmentsPeptidesReproducibility of ResultsAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersGoldPeptide FragmentsPeptidesBeta-amyloidBloodClinical diagnosisNanoparticlesNeurodegenerative diseasePathophysiologyPeptisensorβ-Amyloid(1–42)

Identifiers

PMID31713687
OpenAlexW2983963013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.